Clinical Trial Update: To Evaluate Safety and Efficacy of Autologous CD19 Chimeric Antigen Receptor (CAR)-T Cells in Relapsed/Refractory B- Non-Hodgkin Lymphoma (B-NHL) [Phase 2]

View source ↗

Summary

A Phase 2 trial is evaluating the safety and efficacy of autologous CD19 CAR-T cells for relapsed/refractory B-cell non-Hodgkin lymphoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Non-hodgkin Lymphoma

Drugs mentioned

• Autologous CD19 CAR-T Cells (CD19 CAR-T cells)

Snippet

Sponsor: National University of Malaysia | Conditions: Relapsed/Refractory B- Cell Non-Hodgkin Lymphoma | Phase 2 | Status: RECRUITING